Janus Henderson Investors logo

Janus Henderson Investors

Europe, England, United Kingdom, London

Description

Janus Henderson Investors is an asset manager that helps their clients achieve their financial goals.

Investor Profile

Janus Henderson Investors has backed more than 168 startups, with 19 new investments in the last 12 months alone. The firm has led 16 rounds, about 10% of its total and boasts 97 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series B, Post Ipo Equity, Series C rounds (top funding stages).
  • Majority of deals are located in United States, Canada, United Kingdom.
  • Strong thematic focus on Biotechnology, Health Care, Medical.
  • Led 2 rounds in the past year.

Stage Focus

  • Series B (30%)
  • Post Ipo Equity (29%)
  • Series C (17%)
  • Series A (12%)
  • Series D (6%)
  • Series Unknown (2%)
  • Private Equity (1%)
  • Series E (1%)
  • Series F (1%)
  • Series G (1%)

Country Focus

  • United States (88%)
  • Canada (3%)
  • United Kingdom (2%)
  • China (2%)
  • Singapore (1%)
  • Denmark (1%)
  • The Netherlands (1%)
  • Spain (1%)
  • India (1%)
  • Germany (1%)

Industry Focus

  • Biotechnology
  • Health Care
  • Medical
  • Therapeutics
  • Pharmaceutical
  • Life Science
  • Biopharma
  • Oncology
  • Health Diagnostics
  • Genetics
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Janus Henderson Investors frequently co-invest with?

OrbiMed
North America, New York, United States, New York
Co-Investments: 29
Wellington Management
North America, Massachusetts, United States, Boston
Co-Investments: 28
Surveyor Capital
North America, Illinois, United States, Chicago
Co-Investments: 38
CA
North America, Massachusetts, United States, Boston
Co-Investments: 44
Adage Capital Management
North America, Massachusetts, United States, Boston
Co-Investments: 24
Biotechnology Value Fund
North America, California, United States, San Francisco
Co-Investments: 25
RA Capital Management
North America, Massachusetts, United States, Boston
Co-Investments: 61
Perceptive Advisors
North America, New York, United States, New York
Co-Investments: 25
Logos Capital
North America, California, United States, San Francisco
Co-Investments: 55
Boxer Capital
North America, Florida, United States, Windermere
Co-Investments: 28

Which angels does Janus Henderson Investors often collaborate with?

PT
North America, California, United States, San Francisco
Shared Deals: 1
SK
North America, California, United States, Los Angeles
Shared Deals: 1
JR
North America, California, United States, San Francisco
Shared Deals: 1
RK
North America, California, United States, Los Angeles
Shared Deals: 1

What are some of recent deals done by Janus Henderson Investors?

Izertis

Gijón, Asturias, Spain

Izertis is a technology consulting company that helps organizations with their digital transformation.

Artificial Intelligence (AI)ConsultingCyber SecurityDigital MarketingInformation TechnologyQuality AssuranceSoftware
Post Ipo EquityJan 29, 2026
Amount Raised: $64,730,340
Tenpoint Therapeutics

Camborne, Cornwall, United Kingdom

Tenpoint Therapeutics is a biotechnology company pursuing vision-restoring engineered cell-based therapeutics.

BiotechnologyProduct Research
Series BJan 28, 2026
Amount Raised: $85,000,000
TRex Bio

South San Francisco, California, United States

TRex Bio is a biotechnology company that treats diseases like cancer, fibrotic by studying human tissues.

BioinformaticsBiopharmaBiotechnology
Series UnknownJan 27, 2026
Amount Raised: $50,000,000
Think Bioscience

Boulder, Colorado, United States

Think Bioscience is reimagining synthetic biology by guiding the design and assembly of better medicines through the use of living systems.

BiotechnologyLife ScienceTherapeutics
Series AJan 20, 2026
Amount Raised: $55,000,000
Caldera Therapeutics

Cambridge, Massachusetts, United States

Caldera Therapeutics is a biotech company engaged in the development of bispecific antibody CLD-423 for inflammatory bowel disease (IBD).

BiopharmaBiotechnologyLife Science
Series AJan 14, 2026
Amount Raised: $37,500,000
Parabilis Medicines

Cambridge, Massachusetts, United States

Parabilis Medicines is a Grupo Bugio is a biopharmaceutical firm that specializes in creating medicines.

BiopharmaBiotechnologyHealth CareLife ScienceMedicalPharmaceuticalPrecision Medicine
Series FJan 8, 2026
Amount Raised: $305,000,000
Diagonal Therapeutics

Watertown, Massachusetts, United States

Diagonal Therapeutics is a biotechnology startup that develops targeted therapies for cancer and genetic diseases.

BiopharmaBiotechnologyLife ScienceMedicalTherapeutics
Series BJan 8, 2026
Amount Raised: $125,000,000
CAMP4 Therapeutics

Cambridge, Massachusetts, United States

CAMP4 Therapeutics is a biotechnology company that uses RNA to restore healthy gene expression.

BiopharmaBiotechnologyTherapeutics
Post Ipo EquityDec 18, 2025
Amount Raised: $30,000,000
Yarrow

New York, New York, United States

Yarrow is developing a first-in-class antibody targeting TSHR for the treatment of Graves’ disease and thyroid eye disease.

Business IntelligenceHealth CareMedical
Series UnknownDec 17, 2025
Amount Raised: $200,000,000
Ambros Therapeutics

Irvine, California, United States

Ambros Therapeutics is a clinical-stage biotechnology company.

BiotechnologyMedicalTherapeutics
Series ADec 16, 2025
Amount Raised: $125,000,000

Find More Investors Like Janus Henderson Investors

Discover similar investors in our database and build your perfect investor list.

Need help with your fundraising strategy?Read our fundraising guides

Janus Henderson Investors | Pipeseed